Criteria for Drugs Used in Pre-exposure Prophylaxis Trials Against HIV Infection

Overview

Journal PLoS Med

Specialty General Medicine

Date 2006 Nov 9

PMID 17090213

Citations 23

Authors

Inge Derdelinckx

Mark A Wainberg

Joep M A Lange

Andrew Hill

Yasmin Halima

Charles A B Boucher

Affiliations

Soon will be listed here.

Citing Articles

Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.

Mujugira A, Baeten J, Hodges-Mameletzis I, Haberer J Drugs. 2020; 80(18):1881-1888.

PMID: 33040323 PMC: 7710557. DOI: 10.1007/s40265-020-01419-4.

Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?.

Franconi I, Guaraldi G Drugs Aging. 2018; 35(6):485-491.

PMID: 29736816 DOI: 10.1007/s40266-018-0553-3.

Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.

Gallay P, Chatterji U, Kirchhoff A, Gandarilla A, Pyles R, Baum M Open Virol J. 2018; 12:1-13.

PMID: 29541273 PMC: 5842390. DOI: 10.2174/1874357901812010001.

Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.

Schauer A, Sykes C, Cottrell M, Prince H, Kashuba A J Pharm Biomed Anal. 2017; 149:40-45.

PMID: 29100029 PMC: 5741486. DOI: 10.1016/j.jpba.2017.10.030.

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.

Gallay P, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles R PLoS One. 2017; 12(9):e0184303.

PMID: 28880948 PMC: 5589224. DOI: 10.1371/journal.pone.0184303.

References

Dhawan D, Mayer K . Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J Infect Dis. 2005; 193(1):36-44. DOI: 10.1086/499163. View

Turner D, Brenner B, Routy J, Moisi D, Rosberger Z, Roger M . Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 37(5):1627-31. DOI: 10.1097/00126334-200412150-00017. View

Kuritzkes D, Quinn J, Benoit S, Shugarts D, Griffin A, Bakhtiari M . Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996; 10(9):975-81. DOI: 10.1097/00002030-199610090-00007. View

Marcelin A, Flandre P, Pavie J, Schmidely N, Wirden M, Lada O . Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother. 2005; 49(5):1739-44. PMC: 1087657. DOI: 10.1128/AAC.49.5.1739-1744.2005. View

Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A . Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005; 2(11):e298. PMC: 1262556. DOI: 10.1371/journal.pmed.0020298. View

Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J . Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999; 13(17):2349-59. DOI: 10.1097/00002030-199912030-00006. View

van t Wout A, Ran L, Nijhuis M, Tijnagel J, de Groot T, van Leeuwen R . Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo. AIDS. 1998; 12(10):1169-76. DOI: 10.1097/00002030-199810000-00009. View

Cohen M . Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet. 1998; 351 Suppl 3:5-7. DOI: 10.1016/s0140-6736(98)90002-2. View

Katzenstein T, Eugen-Olsen J, Hofmann B, Benfield T, Pedersen C, Iversen A . HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16(1):10-4. DOI: 10.1097/00042560-199709010-00002. View

10.

Whitcomb J, Parkin N, Chappey C, Hellmann N, Petropoulos C . Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003; 188(7):992-1000. DOI: 10.1086/378281. View

11.

Kilewo C, Karlsson K, Massawe A, Lyamuya E, Swai A, Mhalu F . Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr. 2008; 48(3):315-23. DOI: 10.1097/QAI.0b013e31816e395c. View

12.

Garcia-Lerma J, Otten R, Qari S, Jackson E, Cong M, Masciotra S . Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008; 5(2):e28. PMC: 2225435. DOI: 10.1371/journal.pmed.0050028. View

13.

Miller C, Li Q, Abel K, Kim E, Ma Z, Wietgrefe S . Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol. 2005; 79(14):9217-27. PMC: 1168785. DOI: 10.1128/JVI.79.14.9217-9227.2005. View

14.

Tsai C, Follis K, Sabo A, Beck T, Grant R, Bischofberger N . Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995; 270(5239):1197-9. DOI: 10.1126/science.270.5239.1197. View

15.

Sproat M, Pozniak A, Peeters M, Winters B, Hoetelmans R, Graham N . The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther. 2005; 10(2):357-61. View

16.

Brenner B, Oliveira M, Doualla-Bell F, Moisi D, Ntemgwa M, Frankel F . HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006; 20(9):F9-13. DOI: 10.1097/01.aids.0000232228.88511.0b. View

17.

Veazey R, Springer M, Marx P, Dufour J, Klasse P, Moore J . Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med. 2005; 11(12):1293-4. DOI: 10.1038/nm1321. View

18.

Brenner B, Routy J, Petrella M, Moisi D, Oliveira M, Detorio M . Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol. 2002; 76(4):1753-61. PMC: 135882. DOI: 10.1128/jvi.76.4.1753-1761.2002. View

19.

Quinn T, Wawer M, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F . Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342(13):921-9. DOI: 10.1056/NEJM200003303421303. View

20.

Van Rompay K, McChesney M, Aguirre N, Schmidt K, Bischofberger N, Marthas M . Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis. 2001; 184(4):429-38. DOI: 10.1086/322781. View